Clinical Data of Healthy Individuals and Patients With HD
| . | . | . | Stage of Disease . | Age (yr) at Analysis . | Age (yr) at Diagnosis . | |||
|---|---|---|---|---|---|---|---|---|
| . | . | . | . | . | . | . | . | . |
| . | . | Sex . | I . | II . | III . | IV . | Median . | Median . |
| Category . | No. . | M:F . | No. Subjects (Symptoms A/B) . | (range) . | (range) . | |||
| . | . | . | . | . | . | . | . | . |
| Healthy controls | 34 | 17:17 | 40.5 | |||||
| (24.8-59.8) | ||||||||
| HD | 19 | 13:6 | 4 | 11 | 1 | 3 | 31.1 | |
| Pretreatment | (4/0) | (11/0) | (1/0) | (3/0) | (17.2-58.9) | |||
| Posttreatment | 56 | 21:35 | 8 | 33 | 9 | 6 | 40.0 | 32.0 |
| (7/1) | (30/3) | (6/3) | (5/1) | (17.3-72.2) | (14.8-50.8) | |||
| . | . | . | Stage of Disease . | Age (yr) at Analysis . | Age (yr) at Diagnosis . | |||
|---|---|---|---|---|---|---|---|---|
| . | . | . | . | . | . | . | . | . |
| . | . | Sex . | I . | II . | III . | IV . | Median . | Median . |
| Category . | No. . | M:F . | No. Subjects (Symptoms A/B) . | (range) . | (range) . | |||
| . | . | . | . | . | . | . | . | . |
| Healthy controls | 34 | 17:17 | 40.5 | |||||
| (24.8-59.8) | ||||||||
| HD | 19 | 13:6 | 4 | 11 | 1 | 3 | 31.1 | |
| Pretreatment | (4/0) | (11/0) | (1/0) | (3/0) | (17.2-58.9) | |||
| Posttreatment | 56 | 21:35 | 8 | 33 | 9 | 6 | 40.0 | 32.0 |
| (7/1) | (30/3) | (6/3) | (5/1) | (17.3-72.2) | (14.8-50.8) | |||
All 56 posttreatment patients received radiation therapy including thymic irradiation. Thirty-two of them also had chemotherapy in addition to radiotherapy (15, Stanford V: nitrogen mustard, adriamycin, vincristine, vinblastine, bleomycin, prednisone, ancillary drugs; 6, MOPP; mechlorethamine, vincristine, procarbazine, prednisone; 4, VBM: vinblastine, bleomycin, methotrexate; 3, PAVe: procarbazine, melphalan, vinblastine; 2, ABVD: doxorubicin, bleomycin, vinblastine, dacarbazine; 2, MOPP/ABVD).